Encompass Health (NYSE:EHC) Price Target Increased to $108.00 by Analysts at Barclays

Encompass Health (NYSE:EHC) had its price objective lifted by Barclays from $101.00 to $108.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an overweight rating on the stock.

EHC has been the subject of a number of other reports. Truist Financial lifted their price target on Encompass Health from $82.00 to $86.00 and gave the company a buy rating in a report on Friday, February 9th. Stephens reissued an overweight rating and issued a $85.00 price target on shares of Encompass Health in a report on Tuesday, January 16th. William Blair reaffirmed an outperform rating on shares of Encompass Health in a report on Wednesday, February 7th. Mizuho lifted their target price on Encompass Health from $93.00 to $95.00 and gave the company a buy rating in a research note on Thursday. Finally, Royal Bank of Canada reaffirmed an outperform rating and set a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health presently has a consensus rating of Buy and an average price target of $88.13.

Encompass Health Stock Performance

Encompass Health stock opened at $82.47 on Thursday. Encompass Health has a 52-week low of $57.55 and a 52-week high of $85.84. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.28. The stock has a fifty day moving average price of $78.25 and a two-hundred day moving average price of $70.96. The firm has a market capitalization of $8.26 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.50 and a beta of 0.94.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the business posted $0.88 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. As a group, analysts anticipate that Encompass Health will post 4.1 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Monday, April 1st were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend was Thursday, March 28th. Encompass Health’s dividend payout ratio (DPR) is currently 16.22%.

Institutional Investors Weigh In On Encompass Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in EHC. Principal Securities Inc. acquired a new stake in shares of Encompass Health in the fourth quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. grew its stake in Encompass Health by 360.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after purchasing an additional 317 shares in the last quarter. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Encompass Health during the 4th quarter worth approximately $30,000. GAMMA Investing LLC bought a new stake in shares of Encompass Health during the 4th quarter worth approximately $33,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in shares of Encompass Health in the 3rd quarter valued at approximately $35,000. 97.25% of the stock is owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.